Nutra Pharma Corp.
NPHC
$0.00
$0.00100.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -21.67% | -46.33% | -53.10% | -37.60% | 28.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.67% | -46.33% | -53.10% | -37.60% | 28.02% |
| Cost of Revenue | 56.45% | -58.16% | -27.75% | -43.29% | -39.66% |
| Gross Profit | -38.52% | -35.22% | -65.86% | -34.70% | 68.62% |
| SG&A Expenses | -9.01% | 2.77% | -34.14% | -79.91% | -7.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.73% | -11.29% | -33.54% | -77.75% | -11.60% |
| Operating Income | -11.46% | -20.41% | 25.93% | 86.27% | 29.89% |
| Income Before Tax | 6.39% | -31.48% | 27.96% | -107.52% | -148.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.39% | -31.48% | 27.96% | -107.52% | -148.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.39% | -31.48% | 27.96% | -107.52% | -148.25% |
| EBIT | -11.46% | -20.41% | 25.93% | 86.27% | 29.89% |
| EBITDA | -14.10% | -23.01% | 25.38% | 86.38% | 30.49% |
| EPS Basic | -- | -- | 0.00% | -100.00% | -100.00% |
| Normalized Basic EPS | -- | -- | -- | -100.00% | -- |
| EPS Diluted | -- | -- | 0.00% | -100.00% | -- |
| Normalized Diluted EPS | -- | -- | -- | -100.00% | -- |
| Average Basic Shares Outstanding | 0.57% | 0.79% | 0.61% | 0.32% | 0.28% |
| Average Diluted Shares Outstanding | 0.57% | 0.79% | 0.61% | -75.47% | -51.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |